Langerhans cell histiocytosis in adults: literature review
https://doi.org/10.17650/1818-8346-2022-17-4-16-32
Abstract
Langerhans cells histiocytosis is a variant of malignant histiocytosis. The course and symptoms vary. patients with localized forms have a better prognosis, because local therapy is effective. patients with multifocal forms of histiocytosis receive systemic drug therapy, which cures some of the patients. This review provides up-to-date data about typical presentation of the organ involvement, diagnosis, course and therapy of various forms of Langerhans cells histiocytosis.
About the Authors
V. G. Potapenko
City Clinical Hospital No. 31
Russian Federation
Russian Federation
3 Prospekt Dinamo, Saint Petersburg 197110
V. V. Baykov
I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
6–8 L’va Tolstogo St., Saint Petersburg 197022
A. V. Zinchenko
I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
6–8 L’va Tolstogo St., Saint Petersburg 197022
N. A. Potikhonova
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency
Russian Federation
Russian Federation
16 2nd Sovetskaya St., Saint Petersburg 191024
References
1. Pileri S.A., Grogan T.M., Harris N.L. et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41(1):1–29. DOI: 10.1046/j.13652559.2002.01418.x
2. Howarth D.M., Gilchrist G.S., Mullan B.P. et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999;(85):2278–90. DOI: 10.1002/(sici)10970142(19990515)85:10<2278::aidcncr25>3.0.co;2u
3. Goyal G., Shah M.V., Hook C.C. et al. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and longterm outcomes. Br J Haematol 2018;182(4):579–81. DOI: 10.1111/bjh.14818
4. Campo E., Harris N.L., Pileri S.A. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2017.
5. Bykov V.L. Private human histology (short review course). Saint Petersburg, 2011. (In Russ.).
6. Golub R., Cumano A. Embryonic hematopoiesis. Blood Cells Mol Dis 2013;51(4):226–31. DOI: 10.1016/j.bcmd.2013.08.004
7. Van de Laar L., Saelens W., De Prijck S. et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissueresident macrophages. Immunity 2016;44(4):755–68. DOI: 10.1016/j.immuni.2016.02.017
8. Collin M., Milne P. Langerhans cell origin and regulation. Curr Opin Hematol 2016;23(1):28–35. DOI: 10.1097/MOH.0000000000000202
9. Langerhans P. Über die Nerven der menschlichen Haut. Arch Abl B Pathol 1868;44:325–37.
10. Churilov L.P. Death on the rise, or Who are you, Dr. Taratynov? Zdorov’e – osnova chelovecheskogo potentsiala: problemy i puti ikh resheniya = Health is the Basis of Human Potential: Problems and Ways to Solve them 2014;9(2):919–29. (In Russ.).
11. CoppesZantinga A., Egeler R.M. The Langerhans cell histiocytosis X files revealed. Br J Haematol 2002;116(1):3–9. DOI: 10.1046/j.13652141.2002.03232.x
12. Diamond E.L., Durham B.H., Haroche J. et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6(2):154–65. DOI: 10.1158/21598290.CD150913
13. Haroche J., Charlotte F., Arnaud L. et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other nonLangerhans cell histiocytoses. Blood 2012;120(13):2700–3. DOI: 10.1182/blood201205430140
14. BadalianVery G., Vergilio J.A., Degar B.A. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116(11):1919–23. DOI: 10.1182/blood201004279083
15. Roden A.C., Hu X., Kip S. et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 2014;38(4):548–51. DOI: 10.1097/PAS.0000000000000129
16. Go H., Jeon Y.K., Huh J. et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 2014;65(2):261–72. DOI: 10.1111/his.12416
17. Héritier S., Emile J.F., Barkaoui M.A. et al. BRAF mutation correlates with highrisk Langerhans cell histiocytosis and increased resistance to firstline therapy. J Clin Oncol 2016;34(25):3023–30. DOI: 10.1200/JCO.2015.65.9508
18. Medeiros L.J., Miranda R.N. Diagnostic pathology: lymph nodes and extranodal lymphomas ebook. Elsevier Health Sciences, 2017.
19. Grace S.A., Sutton A.M., Armbrecht E.S. et al. p53 is a helpful marker in distinguishing Langerhans cell histiocytosis from Langerhans cell hyperplasia. Am J Dermatopathol 2017;39(10):726–30. DOI: 10.1097/DAD.0000000000000778
20. Chatterjee D., Vishwajeet V., Saikia U.N. et al. Is useful to differentiate Langerhans cell histiocytosis from reactive Langerhans cells. Am J Dermatopathol 2019;41(3):188–92. DOI: 10.1097/DAD.0000000000001250
21. Emile J.F., Abla O., Fraitag S. et al. Revised classification of histiocytoses and neoplasms of the macrophagedendritic cell lineages. Blood 2016;127(22):2672–81. DOI: 10.1182/ blood201601690636
22. Aricò M., Girschikofsky M., Généreau T. et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39(16):2341–8. DOI: 10.1016/s09598049(03)006725
23. Potapenko V.G., Klimovich A.V., Evseev D.A. et al. Structure and clinical manifestations of malignant histiocytosis in adults. Gematologiya i transfuziologiya = Hematology and Transfusiology 2022;67(S1):186. (In Russ.).
24. Tazi A., Marc K., Dominique S. et al. Serial CT and lung function testing in pulmonary Langerhans cell histiocytosis. Eur Respir J 2012;40(4):905–12. DOI: 10.1183/09031936.00210711
25. Colby T.V., Lombard C. Histiocytosis X in the lung. Hum Pathol 1983;14(10):847–56. DOI: 10.1016/s00468177(83)801609
26. Amosov V.V. Early radiation diagnosis and monitoring of patients with pulmonary histiocytosis. Dis. … candidate of medical sciences. Moscow, 2017. (In Russ.).
27. Wei P., Lu H.W., Jiang S. et al. Pulmonary Langerhans cell histiocytosis: case series and literature review. Medicine (Baltimore). 2014;93(23):e141. DOI: 10.1097/MD.0000000000000141
28. Von Essen S., West W., Sitorius M. et al. Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X. Chest 1990;98(3):765–7. DOI: 10.1378/chest.98.3.765
29. Delobbe A., Durieu J., Duhamel A. et al. Determinants of survival in pulmonary Langerhans’ cell granulomatosis (histiocytosis X). Groupe d’Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J 1996;9(10):2002–6. DOI: 10.1183/09031936.96.09102002
30. Mogulkoc N., Veral A., Bishop P.W. et al. Pulmonary Langerhans’ cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999;115(5):1452–5. DOI: 10.1378/chest.115.5.1452
31. Sawalha L., Kumar A., Arshad A. et al. Pulmonary Langerhans cell histiocytosis: radiologic resolution following cessation of second hand smoking. Clin Respir J 2017;11(6):1063–7. DOI: 10.1111/crj.12445
32. Vassallo R., Harari S., Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax 2017;72(10):937–45. DOI: 10.1136/thoraxjnl2017210125
33. Liu H., Osterburg A.R., Flury J. et al. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight 2020;5(4):e13204. DOI: 10.1172/jci.insight.132048
34. Mendez J.L., Nadrous H.F., Vassallo R. et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004;125(3):1028–32. DOI: 10.1378/chest.125.3.1028
35. Mason R.H., Foley N.M., Branley H.M. et al. Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register. Thorax 2014;69(8):766–7. DOI: 10.1136/thoraxjnl2013204313
36. Tadokoro A., Ishii T., Bandoh S. et al. Pulmonary Langerhans cell histiocytosis in a nonsmoking Japanese woman. Nihon Kokyuki Gakkai Zasshi 2011;49(3):203–7.
37. Fernandes L., Vadala R., Mesquita A.M. et al. Rare interstitial lung disease: pulmonary Langerhans cell histiocytosis in a young non smoking Indian female. Indian J Tuberc 2015;62(1):46–9. DOI: 10.1016/j.ijtb.2015.02.008
38. Marchal J., Kambouchner M., Tazi A. et al. Expression of apoptosisregulatory proteins in lesions of pulmonary Langerhans cell histiocytosis. Histopathology 2004;45(1):20–8. DOI: 10.1111/j.13652559.2004.01875.x
39. Hogstad B., Berres M.L., Chakraborty R. et al. RAF/MEK/ extracellular signalrelated kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 2018;215(1):319–36. DOI: 10.1084/jem.20161881
40. Samsonova M.V., Chernyaev A.L., Avdeev S.N. et al. Relapse of Langerhans cell histiocytosis after lung transplantation. Prakticheskaya pul’monologiya = Practical Pulmonology 2018;(4):81–5. (In Russ.).
41. Dauriat G., Mal H., Thabut G. et al. Lung transplantation for pulmonary Langerhans’ cell histiocytosis: a multicenter analysis. Transplantation 2006;81(5):746–50. DOI: 10.1097/01. tp.0000200304.64613.af
42. Housini I., Tomashefski J.F.Jr, Cohen A. et al. Transbronchial biopsy in patients with pulmonary eosinophilic granuloma. Comparison with findings on open lung biopsy. Arch Pathol Lab Med 1994;118(5):523–30.
43. Auerswald U., Barth J., Magnussen H. Value of CD1positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 1991;169(6):305–9. DOI: 10.1007/ BF02714167
44. Girschikofsky M., Arico M., Castillo D. et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of EuroHistioNet. Orphanet J Rare Dis 2013;(8):72. DOI: 10.1186/17501172872
45. Casolaro M.A., Bernaudin J.F., Saltini C. et al. Accumulation of Langerhans’cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988;137(2):406–11. DOI: 10.1164/ajrccm/137.2.406
46. Radzikowska E., BłasińskaPrzerwa K., Wiatr E. et al. Pneumothorax in patients with pulmonary Langerhans cell histiocytosis. Lung 2018;196(6):715–20. DOI: 10.1007/s0040801801551
47. Singla A., Kopras E.J., Gupta N. Spontaneous pneumothorax and air travel in pulmonary Langerhans cell histiocytosis: a patient survey. Respir Investig 2019;57(6):582–9. DOI: 10.1016/j. resinv.2019.07.004
48. Chaowalit N., Pellikka P.A., Decker P.A. et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004;79(10):1269–75. DOI: 10.4065/79.10.1269
49. Wajda N., Zhu Z., Jandarov R. et al. Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. Respirology 2020;25(6):644–50. DOI: 10.1111/resp.13671
50. Singh A., Prieto V.G., Czelusta A. et al. Adult Langerhans cell histiocytosis limited to the skin. Dermatology 2003;207(2):157–61. DOI: 10.1159/000071786
51. Caputo R., Gianotti R., Monti M. Nodular “pure” mucocutaneous histiocytosis X in an adult. Arch Dermatol 1987;123(10):1274–5.
52. Chi D.H., Sung K.J., Koh J.K. Eruptive xanthomalike cutaneous Langerhans cell histiocytosis in an adult. J Am Acad Dermatol 1996;34(4):688–9. DOI: 10.1016/s01909622(96)800880
53. Lieberman P.H., Jones C.R., Steinman R.M. et al. Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol 1996;20(5):519–52. DOI: 10.1097/0000047819960500000001
54. Yusupova L.A., Yunusova E.I., Garaeva Z.Sh. et al. Histiocytosis X. Prakticheskaya meditsina = Practical Medicine 2014;8(84):7–10. (In Russ.).
55. Lichtenwald D.J., Jakubovic H.R., Rosenthal D. Primary cutaneous Langerhans cell histiocytosis in an adult. Arch Dermatol 1991;127(10):1545–8.
56. Hashimoto K., Kagetsu N., Taniguchi Y. et al. Immunohistochemistry and electron microscopy in Langerhans cell histiocytosis confined to the skin. J Am Acad Dermatol 1991;25(6 Pt 1): 1044–53. DOI: 10.1016/01909622(91)70305l
57. Kunst M.A., Akhmerov S.F., Badeeva M.Yu. et al. A case of cutaneous Langerhans cell histiocytosis (Histiocytosis X). Prakticheskaya meditsina = Practical Medicine 2011;(55):195–7. (In Russ.).
58. Reisi N., Raeissi P., Harati Khalilabad T. et al. Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature. Orphanet J Rare Dis 2021;16(1):1. DOI: 10.1186/s1302302001625z
59. Salam H., Shahid R., Mirza T. Langerhans cell histiocytosis involving both jaws in an adult. J Coll Physicians Surg Pak 2017;27(9):S89–91.
60. Saunders J.G., Eveson J.W., Addy M. et al. Langerhans cell histiocytosis presenting as bilateral eosinophilic granulomata in the molar region of the mandible. A case report. J Clin Periodontol 1998;25(4):340–2. DOI: 10.1111/j.1600051x.1998.tb02451.x
61. Peters S.M., Pastagia J., Yoon A.J. et al. Langerhans cell histiocytosis mimicking periapical pathology in a 39yearold man. J Endod 2017;43(11):1909–14. DOI: 10.1016/j.joen.2017.05.020
62. Nangalia R., Chatterjee R.P., Kundu S. et al. Langerhans cell histiocytosis in an adult with oral cavity involvement: posing a diagnostic challenge. Contemp Clin Dent 2019;10(1):154–7. DOI: 10.4103/ccd.ccd_432_18
63. Eckardt A., Schultze A. Maxillofacial manifestations of Langerhans cell histiocytosis: a clinical and therapeutic analysis of 10 patients. Oral Oncol 2003;39(7):687–94. DOI: 10.1016/s13688375(03)000800
64. Kim J.E., Yi W.J., Heo M.S. et al. Langerhans cell histiocytosis of the jaw, a mimicker of osteomyelitis on CT and MR images: a retrospective analysis. Medicine (Baltimore) 2019;98(27):e16331. DOI: 10.1097/MD.0000000000016331
65. Diab A., Daihes N.A., Saidulaev V.A. et al. Langerhans cell histiocytosis of the temporal bones: a clinical case. Vrach = The Doctor 2022;(1):78–80. (In Russ.). DOI: 10.29296/2587730520220113
66. Dogan A.S., Conway J.J., Miller J.H. et al. Detection of bone lesions in Langerhans cell histiocytosis: complementary roles of scintigraphy and conventional radiography. J Pediatr Hematol Oncol 1996;18(1):51–8. DOI: 10.1097/0004342619960200000010
67. Goo H.W., Yang D.H., Ra Y.S. et al. Wholebody MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36(10):1019–31. DOI: 10.1007/s0024700602467
68. Kim J.R., Yoon H.M., Jung A.Y. et al. Comparison of wholebody MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep 2019;9(1):317. DOI: 10.1038/s41598018365011
69. Jessop S., Crudgington D., London K. et al. FDG PETCT in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 2020;67(1):e28034. DOI: 10.1002/pbc.28034
70. Ferrell J., Sharp S., Kumar A. et al. Discrepancies between F18FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis. Pediatr Blood Cancer 2021;68(4):e28891. DOI: 10.1002/pbc.28891
71. Mayer S., Raggio B.S., Master A. et al. Langerhans cell histiocytosis of the temporal bone. Ochsner J 2020;20(3):315–8. DOI: 10.31486/ toj.19.0032
72. Coleman M.A., Matsumoto J., Carr C.M. et al. Bilateral temporal bone langerhans cell histiocytosis: radiologic pearls. Open Neuroimag J 2013;7:53–7. DOI: 10.2174/1874440001307010053
73. Modest M.C., Garcia J.J., Arndt C.S. et al. Langerhans cell histiocytosis of the temporal bone: a review of 29 cases at a single center. Laryngoscope 2016;126(8):1899–904. DOI: 10.1002/lary.25773
74. Key S.J., O’Brien C.J., Silvester K.C. et al. Eosinophilic granuloma: resolution of maxillofacial bony lesions following minimal intervention. Report of three cases and a review of the literature. J Craniomaxillofac Surg 2004;32(3):170–5. DOI: 10.1016/j. jcms.2004.01.004
75. Vaish A., Vaishya R., Singh L.K. et al. Langerhans cell histiocytosis of a metatarsal bone in an adult female. BMJ Case Rep 2019;12(10):e231343. DOI: 10.1136/bcr2019231343
76. Miller M.A., Williams W.W. Eosinophilic granuloma of the hand. J Hand Surg Br 1993;18(6):742–5. DOI: 10.1016/02667681(93)902347
77. Rimondi E., Mavrogenis A.F., Rossi G. et al. CTguided corticosteroid injection for solitary eosinophilic granuloma of the spine. Skeletal Radiol 2011;40(6):757–64. DOI: 10.1007/s0025601010457
78. Mavrogenis A.F., Rimondi E., Ussia G. et al. Successful treatment of a bifocal eosinophilic granuloma of the spine with CTguided corticosteroid injection. Orthopedics 2011;34(3):230. DOI: 10.3928/014774472011012429
79. Esen A., Dolanmaz D., Kalayci A. et al. Treatment of localized Langerhans’ cell histiocytosis of the mandible with intralesional steroid injection: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(2):e53–8. DOI: 10.1016/j.tripleo.2009.10.015
80. Kotecha R., Venkatramani R., Jubran R.F. et al. Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis. Am J Clin Oncol 2014;37(6):592–6. DOI: 10.1097/ COC.0b013e318281d6ce
81. Latyshev V.D., Lukina E.A. Langerhans cell histiocytosis in adults: modern possibilities of therapy. Klinicheskaya onkogematologiya = Clinical Oncohematology 2021;14(4):444–54. (In Russ.). DOI: 10.21320/25002139202114444445
82. Laird J., Ma J., Chau K. et al. Outcome after radiation therapy for langerhans cell histiocytosis is dependent on site of involvement. Int J Radiat Oncol Biol Phys 2018;100(3):670–8. DOI: 10.1016/j.ijrobp.2017.10.053
83. Grois N., Fahrner B., Arceci R.J. et al. Histiocyte Society CNS LCH Study Group. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156(6):873–81.e1. DOI: 10.1016/j. jpeds.2010.03.001
84. A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans’ Cell Histiocytosis Study Group. Arch Dis Child 1996;75(1):17–24. DOI: 10.1136/adc.75.1.17
85. Dhall G., Finlay J.L., Dunkel I.J. et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2chlorodeoxyadenosine. Pediatr Blood Cancer 2008;50(1):72–9. DOI: 10.1002/pbc.21225
86. Lukina L.V., Mikhailov V.A., Anan’eva N.I. et al. A case of fixation amnesia in histiocytosis from Langerhans cells with damage to the central nervous system. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):117–23. (In Russ.). DOI: 10.14412/2074271120206117123
87. Rumboldt Z., Rossi A. Neurodegenerative Langerhans Cell Histiocytosis (NDLCH). In: Brain Imaging with MRI and CT: An Image Pattern Approach. Eds.: Z. Rumboldt, M. Castillo, B. Huang et al. Cambridge: Cambridge University Press, 2012. Pp. 71–72. DOI: 10.1017/CBO9781139030854.036
88. Wnorowski M., Prosch H., Prayer D. et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr 2008;153(1):127–32. DOI: 10.1016/j.jpeds.2007.12.042
89. Latyshev V.D., Chavynchak R.B., Kovrigina A.M. et al. Histiocytosis – timing of diagnosis and demographic characteristics of patients, the experience of the Hematology Research Institute. Materials of the V Congress of Hematologists of Russia. Gematologiya i transfuziologiya = Hematology and Transfusiology 2020;65:164 (In Russ.).
90. Makras P., Terpos E., Kanakis G. et al. Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2012;58(5):819–22. DOI: 10.1002/pbc.23166
91. Alexandraki K.I., Makras P., Protogerou A.D. et al. Cardiovascular risk factors in adult patients with multisystem Langerhanscell histiocytosis: evidence of glucose metabolism abnormalities. QJM 2008;101(1):31–40. DOI: 10.1093/qjmed/hcm118
92. Kaltsas G.A., Powles T.B., Evanson J. et al. Hypothalamopituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000;85(4):1370–6. DOI: 10.1210/jcem.85.4.6501
93. Ma J., Jiang Y., Chen X. et al. Langerhans cell histiocytosis misdiagnosed as liver cancer and pituitary tumor in an adult: а case report and brief review of the literature. Oncol Lett 2014;7(5): 1602–4. DOI: 10.3892/ol.2014.1928
94. Mampaey S., Warson F., Van Hedent E. et al. Imaging findings in Langerhans’ cell histiocytosis of the liver and the spleen in an adult. Eur Radiol 1999;9(1):96–8. DOI: 10.1007/s003300050636
95. König C.W., Pfannenberg C., Trübenbach J. et al. MR cholangiography in the diagnosis of sclerosing cholangitis in Langerhans’ cell histiocytosis. Eur Radiol 2001;11(12):2516–20. DOI: 10.1007/s003300100835
96. Arakawa A., Matsukawa T., Yamashita Y. et al. Periportal fibrosis in Langerhans’ cell histiocytosis mimicking multiple liver tumors: US, CT, and MR findings. J Comput Assist Tomogr 1994;18(1):157–9. DOI: 10.1097/0000472819940100000037
97. Hong L., Sun G., Peng L. et al. Isolated Langerhans cell histiocytosis of the spleen: a case report. Medicine (Baltimore) 2018;97(38):e12378. DOI: 10.1097/MD.0000000000012378
98. Singhi A.D., Montgomery E.A. Gastrointestinal tract langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol 2011;35(2):305–10. DOI: 10.1097/PAS.0b013e31820654e4
99. Geissmann F., Thomas C., Emile J.F. et al. Digestive tract involvement in Langerhans cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr 1996;129(6):836–45. DOI: 10.1016/s00223476(96)700276
100. Hamdan M., Qiao J.C., Fikfak V. Adultonset perianal Langerhans cell histiocytosis presenting as pruritus ani: a case report and review of the literature. J Med Case Rep 2021;15(1):357. DOI: 10.1186/ s13256021029240
101. Shankar U., Prasad M., Chaurasia O.P. A rare case of langerhans cell histiocytosis of the gastrointestinal tract. World J Gastroenterol 2012;18(12):1410–3. DOI: 10.3748/wjg.v18.i12.1410
102. Edelweiss M., Medeiros L.J., Suster S. et al. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol 2007;38(10):1463–9. DOI: 10.1016/j.humpath.2007.03.015
103. Lo W.C., Chen C.C., Tsai C.C. et al. Isolated adult Langerhans’ cell histiocytosis in cervical lymph nodes: should it be treated? J Laryngol Otol 2009;123(9):1055–7. DOI: 10.1017/S0022215108004155
104. Guo J.J., Zhu H.Y., Wang L. et al. The clinical and laboratory characteristics of adult Langerhans cell histiocytosis patients and the influencing factors of prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020;28(6):2079–83. DOI: 10.19746/j.cnki.issn.10092137.2020.06.046
105. Haupt R., Minkov M., Astigarraga I. et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical workup, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013;60(2):175–84. DOI: 10.1002/pbc.24367
106. Cao X.X., Li J., Zhao A.L. et al. Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: a single arm, single center, prospective phase 2 study. Am J Hematol 2020;95(9):E235–8. DOI: 10.1002/ajh.25864
107. Magaton I.M., Tzankov A., Krasniqi F. et al. Spontaneous remission of severe systemic Langerhans cell histiocytosis with bladder involvement: a case study. Case Rep Oncol 2017;10(3):876–84. DOI: 10.1159/000480696
108. Gnanasekhar J.D., Ahmad M.S., Reddy R.R. Multifocal Langerhans cell histiocytosis of the jaws: a case report. Quintessence Int 1991;22(7):559–64.
109. Shteinberg M., Yeremekno D., Adir Y. Spontaneous resolution of pulmonary Langerhans cell histiocytosis despite smoking. Lung 2016;194(2):331–2. DOI: 10.1007/s0040801698458
110. Histiocytosis Association. Langerhans cell histiocytosis in children. Available at: https://www.histio.org/page.aspx?pid=380.
111. Steen A.E., Steen K.H., Bauer R. et al. Successful treatment of cutaneous Langerhans cell histiocytosis with lowdose methotrexate. Br J Dermatol 2001;145(1):137–40. DOI: 10.1046/j.13652133.2001.04298.x
112. Zinn D.J., Grimes A.B., Lin H. et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood 2016;128(20): 2462–5. DOI: 10.1182/blood201606721993
113. Farrugia M.K., Morrison C., HernandezIlizaliturri F. et al. A doseresponse relationship to radiotherapy for cutaneous lesions of Langerhans cell histiocytosis. Case Rep Oncol Med 2021;2021:6680635. DOI: 10.1155/2021/6680635
114. Nakajima K., Morisawa R., Kodama H. et al. Successful treatment with cyclophosphamide of Langerhans cell histiocytosis involving the skin and lymph nodes in an adult patient. Clin Exp Dermatol 2010;35(7):791–2. DOI: 10.1111/j.13652230.2010.03802.x
115. Chang S.E., Koh G.J., Choi J.H. et al. Widespread skinlimited adult Langerhans cell histiocytosis: longterm followup with good response to interferon alpha. Clin Exp Dermatol 2002;27(2):135–7. DOI: 10.1046/j.13652230.2002.00989.x
116. Rees J., Paterson A.W. Langerhans cell histiocytosis in an adult. Br J Oral Maxillofac Surg 2009;47(1):52–3. DOI: 10.1016/j.bjoms. 2008.04.010
117. Salama H.A., Jazieh A.R., Alhejazi A.Y. et al. Highlights of the management of adult histiocytic disorders: Langerhans cell histiocytosis, Erdheim–Chester disease, Rosai–Dorfman disease, and hemophagocytic lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 2021;21(1):e66–75. DOI: 10.1016/j.clml.2020.08.007
118. Allen C.E., Ladisch S., McClain K.L. How I treat Langerhans cell histiocytosis. Blood 2015;126(1):26–35. DOI: 10.1182/blood201412569301
119. Go R.S., Jacobsen E., Baiocchi R. et al. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(11):1277–303. DOI: 10.6004/jnccn.2021.0053
120. Carrera C.J., Terai C., Lotz M. et al. Potent toxicity of 2–chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest 1990;86(5):1480–8. DOI: 10.1172/JCI114865
121. Goyal G., Abeykoon J.P., Hu M. et al. Singleagent cladribine as an effective frontline therapy for adults with Langerhans cell histiocytosis. Am J Hematol 2021;96(5):E146–50. DOI: 10.1002/ajh.26119
122. Adam Z., Szturz P., Duraš J. et al. Léčba histiocytózy z Langerhansových buněk kladribinem dosáhla u 9 z 10 dospělých pacientů dlouhodobé kompletní remise [Treatment of Langerhans cells histiocytosis by cladribin reached long–term complete remission in 9 out of 10 adult patients (In Czech)]. Klin Onkol 2012;25(4):255–61.
123. Saven A., Burian C. Cladribine activity in adult Langerhanscell histiocytosis. Blood 1999;93(12):4125–30.
124. Néel A., Artifoni M., Fontenoy A.M. et al. Longterm efficacy and safety of 2CdA (cladribine) in extrapulmonary adultonset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. Br J Haematol 2020;189(5):869–78. DOI: 10.1111/bjh.16449
125. Cytarabine. Instructions for use. Available at: https://www.rlsnet.ru/drugs/citarabin–798. (In Russ.).
126. Ogura M., Morishima Y., Kobayashi Y. et al. Cladribine Study Group. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent nonHodgkin’s lymphomas: results of a Japanese phase II study. Int J Hematol 2004;80(3):267–77. DOI: 10.1532/ijh97.04077
127. Cantu M.A., Lupo P.J., Bilgi M. et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One 2012;7(8):e43257. DOI: 10.1371/journal.pone.0043257
128. Martin M., Pennington K., Vassallo R. Pulmonary Langerhans cell histiocytosis: is marijuana smoking a risk factor? Teasers in diffuse lung disease, 2020. Abstract A3303. DOI: 10.1164/ajrccmconference.2020.201.1_MeetingAbstracts.A3303
129. Rumyantsev A.G., Maschan A.A., Maschan M.A. et al. Federal clinical guidelines for the treatment of LCH in children. Moscow, 2015. (In Russ.).
130. Radzikowska E., Wiatr E., Bestry I. et al. The results of treatment with vinbalstine prednisone and mercaptopurine in adult patients with multisystem langerhans cell histiocytosis. Pediatric Blood Cancer 2014;61(11):2138.
131. Tazi A., Lorillon G., Haroche J. et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis 2017;12(1):95. DOI: 10.1186/s130230170651z
132. Duan M.H., Han X., Li J. et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as firstline treatment for adult Langerhans cell histiocytosis: a singlecenter retrospective study. Leuk Res 2016;42:43–6. DOI: 10.1016/j.leukres.2016.01.012
133. Kemps P.G., Picarsic J., Durham B.H. et al. ALKpositive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 2022;139(2):256–80. DOI: 10.1182/blood.2021013338
134. Diamond E.L., Subbiah V., Lockhart A.C. et al. Vemurafenib for BRAF V600mutant Erdheim–Chester disease and Langerhans cell histiocytosis: analysis of data from the histologyindependent, phase 2, openlabel VEBASKET study. JAMA Oncol 2018;4(3):384–8. DOI: 10.1001/jamaoncol.2017.5029
135. Latyshev V.D., Chavynchak R.D., Averbukh O.M. et al. Trametinib therapy for Langerhans cell histiocytosis and Erdheim–Chester disease in adults. Materials of the VI Congress of Hematologists of Russia. Gematologiya i transfuziologiya = Hematology and Transfusiology 2022;67(S1):50. (In Russ.).
136. Hazim A.Z., Ruan G.J., Ravindran A. et al. Efficacy of BRAFInhibitor therapy in BRAFV600Emutated adult Langerhans cell histiocytosis. Oncologist 2020;25(12):1001–4. DOI: 10.1002/onco.13541
137. Morrison S., Gray A., Greiling T.M. Improvement of primary vulvar Langerhans cell histiocytosis with lenalidomide. Int J Womens Dermatol 2021;7(5Part B):838–40. DOI: 10.1016/j. ijwd.2021.09.010
138. Lair G., Marie I., Cailleux N. et al. Histiocytose langerhansienne de l’adulte: localisations cutanéomuqueuses régressives après traitement par thalidomide [Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide (In French)]. Rev Med Interne 1998;19(3):196–8. DOI: 10.1016/s02488663(97)807205
139. Alioua Z., Hjira N., Oumakhir S. et al. Efficacité du thalidomide dans le traitement de l’histiocytose langerhansienne multisystémique de l’adulte: à propos d’une observation [Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report (In French)]. Rev Med Interne 2006;27(8):633–6. DOI: 10.1016/j.revmed.2006.01.022
140. Jacobsen E., Redd R., Nicotra A. et al. A phase II trial of lenalidomide in adults with histiocyte disorders. Pediatric Blood Cancer 2017;64:S14–5. DOI: 10.1002/pbc.26770
141. Da Costa C.E., Annels N.E., Faaij C.M. et al. Presence of osteoclastlike multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 2005;201(5):687–93. DOI: 10.1084/jem.20041785
142. Chellapandian D., Makras P., Kaltsas G. et al. Bisphosphonates in Langerhans cell histiocytosis: an international retrospective case series. Mediterr J Hematol Infect Dis 2016;8(1):e2016033. DOI: 10.4084/MJHID.2016.033
143. Montella L., Merola C., Merola G. et al. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 2009;27(1):110–3. DOI: 10.1007/s0077400800012
144. Makras P., Tsoli M., Anastasilakis A.D. et al. Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism 2017;69:107–11. DOI: 10.1016/j.metabol.2017.01.004
145. ArenzanaSeisdedos F., Barbey S., Virelizier J.L. et al. Histiocytosis X. Purified (T6+) cells from bone granuloma produce interleukin 1 and prostaglandin E2 in culture. J Clin Invest 1986;77(1):326–9. DOI: 10.1172/JCI112296
146. De Benedittis D., Mohamed S., Rizzo L. et al. Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH). Br J Haematol 2020;191(5):e109–13. DOI: 10.1111/bjh.17067
Review
For citations:
Potapenko V.G., Baykov V.V., Zinchenko A.V., Potikhonova N.A. Langerhans cell histiocytosis in adults: literature review. Oncohematology. 2022;17(4):16-32. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-4-16-32
Views:
9564
Email this article 